BioSpace News Archive

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the pricing of its public offering of 2,758,620 units at a price to the public of $7.25 per

National Comprehensive Cancer Network Foundation’s annual Young Investigator Awards granted to top early-career researchers from leading cancer centers seeking tomorrow’s cures

Quanta, Inc. (OTCPK:QNTA), an applied sciences company based on a quantum biology platform that significantly boosts the potency and efficiency of any plant-based matter, today announced a virtual “Town Hall” style investor event, which will be broadcast live over the internet on May 21, 2020 at 1:30 PM ET. Eric Rice,

A Complimentary Continuing Education Credit Program for EEG Technologists [20-May-2020] IRVING, Texas , May 20, 2020 /PRNewswire/ -- Stratus, a leading neurodiagnostic testing company and the largest provider of in-home EEG testing services in the United States , announces the sponsorship of EEG University (EEG U.) EEG University is an educational program and resourc

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 10 June 2020, at 10:00 hours CEST at Thon Hotel Slottsparken, Wergelandsveien 5 in Oslo.

Cyxone, a Swedish biotech in autoimmune diseases, announces that Tara Heitner PhD MBA has been appointed new CEO for the company by Board of Directors.

Proceeds will enable the company to meet growing demand for its automated microbial detection platform, currently used by a majority of the top 20 global biopharmaceutical companies, and support new product development for pandemic response.

The MEDICREA® Group, pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI proprietary software platform, services and technologies, reports its unaudited results for the first quarter of 2020.

Company using its unique discovery engine for development of therapeutic antibodies and vaccines for neurodegenerative diseases as well as COVID-19 antibody testing

BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining a novel vaccine platform to selectively deliver antigens of interest to immune cells to induce immune responses toward pathogens including SARS-CoV-2 virus or cancer cells, or reduce immune responses in the case of autoimmune or allergic diseases.